Abstract
Obesity is a complex metabolic disorder characterized by an imbalance in energy homeostasis, abnormal increase of adipose tissue, and dysregulation of hormones, cytokines, and other important signaling systems. The increasing prevalence of overweight and obesity is associated with many diet-related chronic diseases, including diabetes mellitus, hepatic steatosis, cardiovascular risk, sleep apnea, stroke, hypertension, and certain cancers. This disease is characterized by leptin and insulin resistance, and appears to be associated with a dysregulated and hyperactive endocannabinoid system, in rodents and humans. Animal studies and clinical trials have shown that blockade of CB1 cannabinoid receptor induces weight loss, improves cardiometabolic risk factors and insulin resistance, and causes metabolic benefits in mammals. Then, blockade of CB1 receptor is considered a challenged strategy in obesity. Thus, the design, molecular structure and pharmacology of novel CB1 antagonists and CB1 inverse agonists are being reported. Moreover, novel cannabinoid targets to develop antiobesity drugs, such as CB2 cannabinoid receptor, the putative cannabinoid GPR55 receptor, and 2-monoacylglycerol lipase, are being taken into account.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
